What significant change was made by PDUFA V, reauthorized by FDASIA?

The significant change made by PDUFA V, as reauthorized by FDASIA, was the authorization for the FDA to collect user fees for drug applications, which supports the agency's commitment to certain review timelines. PDUFA, or the Prescription Drug User Fee Act, initially allowed the FDA to collect fees from pharmaceutical companies to expedite the drug approval process. With PDUFA V, there was a refinement of this approach, which included enhancements in the review process and the establishment of performance goals to ensure timely reviews. The user fees play a key role in enabling the FDA to allocate resources more effectively, thereby improving the efficiency and speed of the drug review process.

This option reflects the ongoing evolution of funding mechanisms that support regulatory operations, ultimately leading to a more streamlined approval pathway for new drugs. The commitments to review timelines provided an assurance from the FDA to industry stakeholders, promoting transparency and accountability in the drug approval process.